Traders Buy High Volume of Annexon Call Options (NASDAQ:ANNX)

Posted by Francis Steltz on Aug 12th, 2026

Annexon, Inc. (NASDAQ:ANNX – Get Free Report) was the target of unusually large options trading on Wednesday. Investors bought 2,592 call options on the company. This is an increase of 244% compared to the typical daily volume of 754 call options.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Citigroup assumed coverage on shares of Annexon in a report on Tuesday, July 21st. They set a “market underperform” rating for the company. Wall Street Zen lowered shares of Annexon from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research report on Friday, July 17th. Needham & Company LLC upped their price objective on shares of Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Citizens Jmp initiated coverage on shares of Annexon in a report on Tuesday, July 21st. They set a “market underperform” rating and a $3.00 target price for the company. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Annexon currently has a consensus rating of “Hold” and an average price target of $15.33.

Read Our Latest Report on Annexon

Insiders Place Their Bets

In related news, Director Muneer A. Satter acquired 613,497 shares of the stock in a transaction on Thursday, May 28th. The stock was purchased at an average price of $5.41 per share, for a total transaction of $3,319,018.77. Following the completion of the transaction, the director owned 10,342,134 shares of the company’s stock, valued at $55,950,944.94. This trade represents a 6.31% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.31% of the company’s stock.

Hedge Funds Weigh In On Annexon

Hedge funds and other institutional investors have recently modified their holdings of the stock. Landscape Capital Management L.L.C. bought a new position in Annexon in the second quarter worth about $119,000. Ieq Capital LLC bought a new stake in Annexon during the 2nd quarter valued at approximately $685,000. E Fund Management Co. Ltd. purchased a new position in shares of Annexon during the 2nd quarter worth approximately $140,000. BlackRock Inc. purchased a new position in shares of Annexon during the 2nd quarter worth approximately $77,312,000. Finally, Deutsche Bank AG bought a new position in shares of Annexon in the 2nd quarter worth approximately $3,520,000.

Annexon Stock Performance

ANNX stock traded up $0.01 on Wednesday, reaching $5.34. The company’s stock had a trading volume of 1,010,674 shares, compared to its average volume of 2,933,415. The business has a fifty day simple moving average of $5.35 and a two-hundred day simple moving average of $5.54. Annexon has a 12-month low of $2.03 and a 12-month high of $7.18. The firm has a market cap of $875.74 million, a PE ratio of -4.38 and a beta of 1.18.

Annexon (NASDAQ:ANNX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). As a group, research analysts anticipate that Annexon will post -0.92 earnings per share for the current fiscal year.

About Annexon

(Get Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.